Physician profile
Robin L Morrison
NPI 1093827560
$13,300.12
in general payments reported to CMS, 2019-2025
45 companies · $2,961 in 2025
The $2,961 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,314 · 2022: $2,651 · 2023: $3,441 · 2024: $2,934 · 2025: $2,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,276 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,275.94 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,888.45 | 2022-2025 | Ozempic, Rybelsus, Sogroya |
| Lilly USA, LLC | $1,415.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $1,015.01 | 2022-2025 | Korlym |
| Amgen INC. | $895.72 | 2021-2025 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $839.49 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $832.17 | 2022-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $709.64 | 2021-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Abbott Laboratories | $700.33 | 2022-2025 | Freestyle Libre, Freestyle Libre 3, Eterna |
| Bayer Healthcare Pharmaceuticals INC. | $545.07 | 2021-2025 | |
| Ascensia Diabetes Care US INC. | $542.11 | 2022-2025 | |
| Dexcom, INC. | $506.11 | 2021-2024 | Dexcom G6 Transmitter |
| Cequr Corporation | $447.25 | 2023-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $424.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $340.84 | 2021-2022 | |
| Mannkind Corporation | $250.76 | 2022-2023 | Afrezza |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.65 | 2021-2025 | Jardiance |
| Abbvie INC. | $157.50 | 2021-2022 | |
| Horizon Therapeutics Plc | $151.18 | 2021-2023 | |
| Nevro Corp. | $134.94 | 2022 | |
| Recordati_rare_diseases_inc. | $124.48 | 2022-2025 | Isturisa, Signifor Lar |
| Regeneron Healthcare Solutions, INC. | $106.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $93.36 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $91.11 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $87.42 | 2025 | |
| Sequel Med Tech, LLC | $77.84 | 2025 | Twiist |
| Amphastar Pharmaceuticals, INC. | $69.11 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $66.25 | 2023-2024 | |
| Radius Health, INC. | $62.84 | 2023-2025 | Tymlos |
| Chiesi USA, INC. | $60.30 | 2024-2025 | Mycapssa, Myalept |
| Amryt Pharma Holdings LTD | $53.28 | 2022-2023 | Mycapssa |
| Eusa Pharma (US) LLC | $48.63 | 2022 | |
| Antares Pharma, INC. | $42.40 | 2025 | Xyosted |
| Almatica Pharma LLC | $40.14 | 2024-2025 | Teriparatide |
| Averitas Pharma INC. | $36.96 | 2023-2024 | Qutenza |
| Amneal Pharmaceuticals LLC | $36.01 | 2023-2024 | Unithroid |
| Azurity Pharmaceuticals, INC. | $33.98 | 2022-2023 | Triptodur |
| Ibsa Pharma INC. | $32.06 | 2021-2023 | Tirosint, Licart |
| Verity Pharmaceuticals INC. | $28.67 | 2025 | Tlando |
| Optos, INC. | $23.28 | 2021 | |
| Halozyme INC | $22.93 | 2023 | |
| Kyowa Kirin, INC. | $20.52 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.00 | 2025 | Yorvipath |
| Grt US Holding, INC. | $17.27 | 2022 | |
| Acella Pharmaceuticals, LLC | $16.86 | 2025 | NP Thyroid 60 |
| Rhythm Pharmaceuticals, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.